TW201639868A - 來自muc1之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法 - Google Patents
來自muc1之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法 Download PDFInfo
- Publication number
- TW201639868A TW201639868A TW105107134A TW105107134A TW201639868A TW 201639868 A TW201639868 A TW 201639868A TW 105107134 A TW105107134 A TW 105107134A TW 105107134 A TW105107134 A TW 105107134A TW 201639868 A TW201639868 A TW 201639868A
- Authority
- TW
- Taiwan
- Prior art keywords
- peptide
- amino acid
- ser
- ala
- thr
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 139
- 206010028980 Neoplasm Diseases 0.000 title claims description 49
- 201000011510 cancer Diseases 0.000 title claims description 44
- 210000000612 antigen-presenting cell Anatomy 0.000 title claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 34
- 238000004519 manufacturing process Methods 0.000 title claims description 12
- 230000036039 immunity Effects 0.000 title claims description 11
- 239000000411 inducer Substances 0.000 title description 4
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 21
- 150000001413 amino acids Chemical group 0.000 claims description 46
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 43
- 230000001939 inductive effect Effects 0.000 claims description 36
- 235000001014 amino acid Nutrition 0.000 claims description 25
- 229940024606 amino acid Drugs 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 229960005486 vaccine Drugs 0.000 claims description 11
- 230000002163 immunogen Effects 0.000 claims description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- 229930182817 methionine Natural products 0.000 claims description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 239000004474 valine Chemical group 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 238000007792 addition Methods 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 239000003022 immunostimulating agent Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 60
- 238000000034 method Methods 0.000 description 35
- 108010087924 alanylproline Proteins 0.000 description 32
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 30
- 241000282414 Homo sapiens Species 0.000 description 28
- 210000004443 dendritic cell Anatomy 0.000 description 26
- FQNILRVJOJBFFC-FXQIFTODSA-N Ala-Pro-Asp Chemical compound C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N FQNILRVJOJBFFC-FXQIFTODSA-N 0.000 description 21
- BSYKSCBTTQKOJG-GUBZILKMSA-N Arg-Pro-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BSYKSCBTTQKOJG-GUBZILKMSA-N 0.000 description 21
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 21
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 21
- 239000000427 antigen Substances 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- AFMOTCMSEBITOE-YEPSODPASA-N Gly-Val-Thr Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AFMOTCMSEBITOE-YEPSODPASA-N 0.000 description 20
- 239000002157 polynucleotide Substances 0.000 description 20
- 102000040430 polynucleotide Human genes 0.000 description 20
- 108091033319 polynucleotide Proteins 0.000 description 20
- 102100034256 Mucin-1 Human genes 0.000 description 18
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 17
- 108010075704 HLA-A Antigens Proteins 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 15
- 108010060035 arginylproline Proteins 0.000 description 13
- 108010021727 HLA-A*24:02 antigen Proteins 0.000 description 12
- FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 description 12
- OKEWAFFWMHBGPT-XPUUQOCRSA-N Ala-His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CN=CN1 OKEWAFFWMHBGPT-XPUUQOCRSA-N 0.000 description 11
- OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 description 11
- DXTOOBDIIAJZBJ-BQBZGAKWSA-N Pro-Gly-Ser Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(O)=O DXTOOBDIIAJZBJ-BQBZGAKWSA-N 0.000 description 11
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 11
- LVHHEVGYAZGXDE-KDXUFGMBSA-N Thr-Ala-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O)N)O LVHHEVGYAZGXDE-KDXUFGMBSA-N 0.000 description 11
- OFTXTCGQJXTNQS-XGEHTFHBSA-N Val-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N)O OFTXTCGQJXTNQS-XGEHTFHBSA-N 0.000 description 11
- 108010037850 glycylvaline Proteins 0.000 description 11
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- MJJIHRWNWSQTOI-VEVYYDQMSA-N Asp-Thr-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O MJJIHRWNWSQTOI-VEVYYDQMSA-N 0.000 description 10
- 102210042925 HLA-A*02:01 Human genes 0.000 description 10
- NTXIJPDAHXSHNL-ONGXEEELSA-N His-Gly-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NTXIJPDAHXSHNL-ONGXEEELSA-N 0.000 description 10
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 10
- FCCBQBZXIAZNIG-LSJOCFKGSA-N Pro-Ala-His Chemical compound C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O FCCBQBZXIAZNIG-LSJOCFKGSA-N 0.000 description 10
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 10
- SFECXGVELZFBFJ-VEVYYDQMSA-N Pro-Asp-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SFECXGVELZFBFJ-VEVYYDQMSA-N 0.000 description 10
- BRKHVZNDAOMAHX-BIIVOSGPSA-N Ser-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N BRKHVZNDAOMAHX-BIIVOSGPSA-N 0.000 description 10
- GZYNMZQXFRWDFH-YTWAJWBKSA-N Thr-Arg-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O GZYNMZQXFRWDFH-YTWAJWBKSA-N 0.000 description 10
- 108010070944 alanylhistidine Proteins 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 6
- 239000007376 cm-medium Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000001638 lipofection Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 108010063954 Mucins Proteins 0.000 description 5
- 102000015728 Mucins Human genes 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 230000002998 immunogenetic effect Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 108010029020 prolylglycine Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- 108010008707 Mucin-1 Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ANOQEBQWIAYIMV-AEJSXWLSSA-N Ser-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N ANOQEBQWIAYIMV-AEJSXWLSSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 3
- 238000003163 cell fusion method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 108010065135 phenylalanyl-phenylalanyl-phenylalanine Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- PEIBBAXIKUAYGN-UBHSHLNASA-N Ala-Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 PEIBBAXIKUAYGN-UBHSHLNASA-N 0.000 description 2
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- KLYPOCBLKMPBIQ-GHCJXIJMSA-N Asp-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N KLYPOCBLKMPBIQ-GHCJXIJMSA-N 0.000 description 2
- RKXVTTIQNKPCHU-KKHAAJSZSA-N Asp-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O RKXVTTIQNKPCHU-KKHAAJSZSA-N 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- HPJLZFTUUJKWAJ-JHEQGTHGSA-N Glu-Gly-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HPJLZFTUUJKWAJ-JHEQGTHGSA-N 0.000 description 2
- XEKAJTCACGEBOK-KKUMJFAQSA-N Glu-Met-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XEKAJTCACGEBOK-KKUMJFAQSA-N 0.000 description 2
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 2
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- -1 HLA-A*02:01 Proteins 0.000 description 2
- BZKDJRSZWLPJNI-SRVKXCTJSA-N His-His-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O BZKDJRSZWLPJNI-SRVKXCTJSA-N 0.000 description 2
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- VPKIQULSKFVCSM-SRVKXCTJSA-N Leu-Gln-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPKIQULSKFVCSM-SRVKXCTJSA-N 0.000 description 2
- IFMDQWDAJUMMJC-DCAQKATOSA-N Pro-Ala-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O IFMDQWDAJUMMJC-DCAQKATOSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 2
- ZSDXEKUKQAKZFE-XAVMHZPKSA-N Ser-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N)O ZSDXEKUKQAKZFE-XAVMHZPKSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 2
- MNSSBIHFEUUXNW-RCWTZXSCSA-N Val-Thr-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N MNSSBIHFEUUXNW-RCWTZXSCSA-N 0.000 description 2
- 108010044940 alanylglutamine Proteins 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000001808 exosome Anatomy 0.000 description 2
- 108010007811 human immunodeficiency virus p17 gag peptide Proteins 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229940051875 mucins Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 108010053725 prolylvaline Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 108010048818 seryl-histidine Proteins 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000003799 water insoluble solvent Substances 0.000 description 2
- 239000003021 water soluble solvent Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- AJFGLTPLWPTALJ-SSDOTTSWSA-N (2s)-2-azaniumyl-2-(fluoromethyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound FC[C@@](N)(C(O)=O)CC1=CN=CN1 AJFGLTPLWPTALJ-SSDOTTSWSA-N 0.000 description 1
- XNQIOISZPFVUFG-RXMQYKEDSA-N (R)-alpha-methylhistamine Chemical compound C[C@@H](N)CC1=CN=CN1 XNQIOISZPFVUFG-RXMQYKEDSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 1
- NHLAEBFGWPXFGI-WHFBIAKZSA-N Ala-Gly-Asn Chemical compound C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N NHLAEBFGWPXFGI-WHFBIAKZSA-N 0.000 description 1
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 1
- LNNSWWRRYJLGNI-NAKRPEOUSA-N Ala-Ile-Val Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O LNNSWWRRYJLGNI-NAKRPEOUSA-N 0.000 description 1
- IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
- VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 1
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 1
- HCBKAOZYACJUEF-XQXXSGGOSA-N Ala-Thr-Gln Chemical compound N[C@@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O HCBKAOZYACJUEF-XQXXSGGOSA-N 0.000 description 1
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 1
- BOKLLPVAQDSLHC-FXQIFTODSA-N Ala-Val-Cys Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)O)N BOKLLPVAQDSLHC-FXQIFTODSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- OTOXOKCIIQLMFH-KZVJFYERSA-N Arg-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N OTOXOKCIIQLMFH-KZVJFYERSA-N 0.000 description 1
- DXQIQUIQYAGRCC-CIUDSAMLSA-N Arg-Asp-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)CN=C(N)N DXQIQUIQYAGRCC-CIUDSAMLSA-N 0.000 description 1
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 1
- BWMMKQPATDUYKB-IHRRRGAJSA-N Arg-Tyr-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 BWMMKQPATDUYKB-IHRRRGAJSA-N 0.000 description 1
- CGWVCWFQGXOUSJ-ULQDDVLXSA-N Arg-Tyr-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O CGWVCWFQGXOUSJ-ULQDDVLXSA-N 0.000 description 1
- QEYJFBMTSMLPKZ-ZKWXMUAHSA-N Asn-Ala-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O QEYJFBMTSMLPKZ-ZKWXMUAHSA-N 0.000 description 1
- HFPXZWPUVFVNLL-GUBZILKMSA-N Asn-Leu-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O HFPXZWPUVFVNLL-GUBZILKMSA-N 0.000 description 1
- XOQYDFCQPWAMSA-KKHAAJSZSA-N Asn-Val-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOQYDFCQPWAMSA-KKHAAJSZSA-N 0.000 description 1
- FAEIQWHBRBWUBN-FXQIFTODSA-N Asp-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N)CN=C(N)N FAEIQWHBRBWUBN-FXQIFTODSA-N 0.000 description 1
- PYXXJFRXIYAESU-PCBIJLKTSA-N Asp-Ile-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PYXXJFRXIYAESU-PCBIJLKTSA-N 0.000 description 1
- PDIYGFYAMZZFCW-JIOCBJNQSA-N Asp-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N)O PDIYGFYAMZZFCW-JIOCBJNQSA-N 0.000 description 1
- JDDYEZGPYBBPBN-JRQIVUDYSA-N Asp-Thr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JDDYEZGPYBBPBN-JRQIVUDYSA-N 0.000 description 1
- QOJJMJKTMKNFEF-ZKWXMUAHSA-N Asp-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O QOJJMJKTMKNFEF-ZKWXMUAHSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- PCKOTDPDHIBGRW-CIUDSAMLSA-N Gln-Cys-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)N)CN=C(N)N PCKOTDPDHIBGRW-CIUDSAMLSA-N 0.000 description 1
- CLPQUWHBWXFJOX-BQBZGAKWSA-N Gln-Gly-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O CLPQUWHBWXFJOX-BQBZGAKWSA-N 0.000 description 1
- XFAUJGNLHIGXET-AVGNSLFASA-N Gln-Leu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XFAUJGNLHIGXET-AVGNSLFASA-N 0.000 description 1
- AQPZYBSRDRZBAG-AVGNSLFASA-N Gln-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N AQPZYBSRDRZBAG-AVGNSLFASA-N 0.000 description 1
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 1
- VCUNGPMMPNJSGS-JYJNAYRXSA-N Gln-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O VCUNGPMMPNJSGS-JYJNAYRXSA-N 0.000 description 1
- KASDBWKLWJKTLJ-GUBZILKMSA-N Glu-Glu-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O KASDBWKLWJKTLJ-GUBZILKMSA-N 0.000 description 1
- MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 description 1
- XUORRGAFUQIMLC-STQMWFEESA-N Gly-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)O XUORRGAFUQIMLC-STQMWFEESA-N 0.000 description 1
- JMQFHZWESBGPFC-WDSKDSINSA-N Gly-Gln-Asp Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JMQFHZWESBGPFC-WDSKDSINSA-N 0.000 description 1
- LXXANCRPFBSSKS-IUCAKERBSA-N Gly-Gln-Leu Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LXXANCRPFBSSKS-IUCAKERBSA-N 0.000 description 1
- ZQIMMEYPEXIYBB-IUCAKERBSA-N Gly-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN ZQIMMEYPEXIYBB-IUCAKERBSA-N 0.000 description 1
- KAJAOGBVWCYGHZ-JTQLQIEISA-N Gly-Gly-Phe Chemical compound [NH3+]CC(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KAJAOGBVWCYGHZ-JTQLQIEISA-N 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- JPVGHHQGKPQYIL-KBPBESRZSA-N Gly-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 JPVGHHQGKPQYIL-KBPBESRZSA-N 0.000 description 1
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 description 1
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 1
- HUFUVTYGPOUCBN-MBLNEYKQSA-N Gly-Thr-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HUFUVTYGPOUCBN-MBLNEYKQSA-N 0.000 description 1
- PYFIQROSWQERAS-LBPRGKRZSA-N Gly-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(=O)NCC(O)=O)=CNC2=C1 PYFIQROSWQERAS-LBPRGKRZSA-N 0.000 description 1
- SBVMXEZQJVUARN-XPUUQOCRSA-N Gly-Val-Ser Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O SBVMXEZQJVUARN-XPUUQOCRSA-N 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- DZMVESFTHXSSPZ-XVYDVKMFSA-N His-Ala-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DZMVESFTHXSSPZ-XVYDVKMFSA-N 0.000 description 1
- JFFAPRNXXLRINI-NHCYSSNCSA-N His-Asp-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O JFFAPRNXXLRINI-NHCYSSNCSA-N 0.000 description 1
- ORERHHPZDDEMSC-VGDYDELISA-N His-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N ORERHHPZDDEMSC-VGDYDELISA-N 0.000 description 1
- ABCCKUZDWMERKT-AVGNSLFASA-N His-Pro-Met Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(O)=O ABCCKUZDWMERKT-AVGNSLFASA-N 0.000 description 1
- ILUVWFTXAUYOBW-CUJWVEQBSA-N His-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)N)O ILUVWFTXAUYOBW-CUJWVEQBSA-N 0.000 description 1
- IXQGOKWTQPCIQM-YJRXYDGGSA-N His-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N)O IXQGOKWTQPCIQM-YJRXYDGGSA-N 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- VAXBXNPRXPHGHG-BJDJZHNGSA-N Ile-Ala-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)N VAXBXNPRXPHGHG-BJDJZHNGSA-N 0.000 description 1
- QIHJTGSVGIPHIW-QSFUFRPTSA-N Ile-Asn-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N QIHJTGSVGIPHIW-QSFUFRPTSA-N 0.000 description 1
- IDMNOFVUXYYZPF-DKIMLUQUSA-N Ile-Lys-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N IDMNOFVUXYYZPF-DKIMLUQUSA-N 0.000 description 1
- XLXPYSDGMXTTNQ-DKIMLUQUSA-N Ile-Phe-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(O)=O XLXPYSDGMXTTNQ-DKIMLUQUSA-N 0.000 description 1
- XLXPYSDGMXTTNQ-UHFFFAOYSA-N Ile-Phe-Leu Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 XLXPYSDGMXTTNQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- RSFGIMMPWAXNML-MNXVOIDGSA-N Leu-Gln-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RSFGIMMPWAXNML-MNXVOIDGSA-N 0.000 description 1
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 description 1
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 1
- KZZCOWMDDXDKSS-CIUDSAMLSA-N Leu-Ser-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KZZCOWMDDXDKSS-CIUDSAMLSA-N 0.000 description 1
- IWMJFLJQHIDZQW-KKUMJFAQSA-N Leu-Ser-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IWMJFLJQHIDZQW-KKUMJFAQSA-N 0.000 description 1
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 1
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 1
- ZJZNLRVCZWUONM-JXUBOQSCSA-N Leu-Thr-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 1
- LJBVRCDPWOJOEK-PPCPHDFISA-N Leu-Thr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LJBVRCDPWOJOEK-PPCPHDFISA-N 0.000 description 1
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 1
- TUIOUEWKFFVNLH-DCAQKATOSA-N Leu-Val-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(O)=O TUIOUEWKFFVNLH-DCAQKATOSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- PXHCFKXNSBJSTQ-KKUMJFAQSA-N Lys-Asn-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)O PXHCFKXNSBJSTQ-KKUMJFAQSA-N 0.000 description 1
- XFOAWKDQMRMCDN-ULQDDVLXSA-N Lys-Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CC1=CC=CC=C1 XFOAWKDQMRMCDN-ULQDDVLXSA-N 0.000 description 1
- BOJYMMBYBNOOGG-DCAQKATOSA-N Lys-Pro-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O BOJYMMBYBNOOGG-DCAQKATOSA-N 0.000 description 1
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010025538 Malignant ascites Diseases 0.000 description 1
- PTYVBBNIAQWUFV-DCAQKATOSA-N Met-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCSC)N PTYVBBNIAQWUFV-DCAQKATOSA-N 0.000 description 1
- GMMLGMFBYCFCCX-KZVJFYERSA-N Met-Thr-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O GMMLGMFBYCFCCX-KZVJFYERSA-N 0.000 description 1
- NDJSSFWDYDUQID-YTWAJWBKSA-N Met-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N)O NDJSSFWDYDUQID-YTWAJWBKSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MPGJIHFJCXTVEX-KKUMJFAQSA-N Phe-Arg-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O MPGJIHFJCXTVEX-KKUMJFAQSA-N 0.000 description 1
- CDNPIRSCAFMMBE-SRVKXCTJSA-N Phe-Asn-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CDNPIRSCAFMMBE-SRVKXCTJSA-N 0.000 description 1
- ZKSLXIGKRJMALF-MGHWNKPDSA-N Phe-His-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC2=CC=CC=C2)N ZKSLXIGKRJMALF-MGHWNKPDSA-N 0.000 description 1
- SMFGCTXUBWEPKM-KBPBESRZSA-N Phe-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 SMFGCTXUBWEPKM-KBPBESRZSA-N 0.000 description 1
- YTILBRIUASDGBL-BZSNNMDCSA-N Phe-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 YTILBRIUASDGBL-BZSNNMDCSA-N 0.000 description 1
- YCCUXNNKXDGMAM-KKUMJFAQSA-N Phe-Leu-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YCCUXNNKXDGMAM-KKUMJFAQSA-N 0.000 description 1
- AXIOGMQCDYVTNY-ACRUOGEOSA-N Phe-Phe-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 AXIOGMQCDYVTNY-ACRUOGEOSA-N 0.000 description 1
- CBENHWCORLVGEQ-HJOGWXRNSA-N Phe-Phe-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CBENHWCORLVGEQ-HJOGWXRNSA-N 0.000 description 1
- AFNJAQVMTIQTCB-DLOVCJGASA-N Phe-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=CC=C1 AFNJAQVMTIQTCB-DLOVCJGASA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VXCHGLYSIOOZIS-GUBZILKMSA-N Pro-Ala-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 VXCHGLYSIOOZIS-GUBZILKMSA-N 0.000 description 1
- OOLOTUZJUBOMAX-GUBZILKMSA-N Pro-Ala-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OOLOTUZJUBOMAX-GUBZILKMSA-N 0.000 description 1
- CJZTUKSFZUSNCC-FXQIFTODSA-N Pro-Asp-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1 CJZTUKSFZUSNCC-FXQIFTODSA-N 0.000 description 1
- VTFXTWDFPTWNJY-RHYQMDGZSA-N Pro-Leu-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VTFXTWDFPTWNJY-RHYQMDGZSA-N 0.000 description 1
- GFHXZNVJIKMAGO-IHRRRGAJSA-N Pro-Phe-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O GFHXZNVJIKMAGO-IHRRRGAJSA-N 0.000 description 1
- GZNYIXWOIUFLGO-ZJDVBMNYSA-N Pro-Thr-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZNYIXWOIUFLGO-ZJDVBMNYSA-N 0.000 description 1
- VVAWNPIOYXAMAL-KJEVXHAQSA-N Pro-Thr-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VVAWNPIOYXAMAL-KJEVXHAQSA-N 0.000 description 1
- FZXSYIPVAFVYBH-KKUMJFAQSA-N Pro-Tyr-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O FZXSYIPVAFVYBH-KKUMJFAQSA-N 0.000 description 1
- DGDCSVGVWWAJRS-AVGNSLFASA-N Pro-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2 DGDCSVGVWWAJRS-AVGNSLFASA-N 0.000 description 1
- VDHGTOHMHHQSKG-JYJNAYRXSA-N Pro-Val-Phe Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](Cc1ccccc1)C(O)=O VDHGTOHMHHQSKG-JYJNAYRXSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- ZUGXSSFMTXKHJS-ZLUOBGJFSA-N Ser-Ala-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O ZUGXSSFMTXKHJS-ZLUOBGJFSA-N 0.000 description 1
- MWMKFWJYRRGXOR-ZLUOBGJFSA-N Ser-Ala-Asn Chemical compound N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(N)=O)C)CO MWMKFWJYRRGXOR-ZLUOBGJFSA-N 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- YMEXHZTVKDAKIY-GHCJXIJMSA-N Ser-Asn-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO)C(O)=O YMEXHZTVKDAKIY-GHCJXIJMSA-N 0.000 description 1
- BTPAWKABYQMKKN-LKXGYXEUSA-N Ser-Asp-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BTPAWKABYQMKKN-LKXGYXEUSA-N 0.000 description 1
- WBINSDOPZHQPPM-AVGNSLFASA-N Ser-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N)O WBINSDOPZHQPPM-AVGNSLFASA-N 0.000 description 1
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- IOVBCLGAJJXOHK-SRVKXCTJSA-N Ser-His-His Chemical compound C([C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 IOVBCLGAJJXOHK-SRVKXCTJSA-N 0.000 description 1
- MOINZPRHJGTCHZ-MMWGEVLESA-N Ser-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N MOINZPRHJGTCHZ-MMWGEVLESA-N 0.000 description 1
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- RXSWQCATLWVDLI-XGEHTFHBSA-N Ser-Met-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RXSWQCATLWVDLI-XGEHTFHBSA-N 0.000 description 1
- RRVFEDGUXSYWOW-BZSNNMDCSA-N Ser-Phe-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RRVFEDGUXSYWOW-BZSNNMDCSA-N 0.000 description 1
- WNDUPCKKKGSKIQ-CIUDSAMLSA-N Ser-Pro-Gln Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O WNDUPCKKKGSKIQ-CIUDSAMLSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- QUGRFWPMPVIAPW-IHRRRGAJSA-N Ser-Pro-Phe Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QUGRFWPMPVIAPW-IHRRRGAJSA-N 0.000 description 1
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 1
- PURRNJBBXDDWLX-ZDLURKLDSA-N Ser-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CO)N)O PURRNJBBXDDWLX-ZDLURKLDSA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- PCJLFYBAQZQOFE-KATARQTJSA-N Ser-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N)O PCJLFYBAQZQOFE-KATARQTJSA-N 0.000 description 1
- VLMIUSLQONKLDV-HEIBUPTGSA-N Ser-Thr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VLMIUSLQONKLDV-HEIBUPTGSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- LMMDEZPNUTZJAY-GCJQMDKQSA-N Thr-Asp-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O LMMDEZPNUTZJAY-GCJQMDKQSA-N 0.000 description 1
- DCLBXIWHLVEPMQ-JRQIVUDYSA-N Thr-Asp-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DCLBXIWHLVEPMQ-JRQIVUDYSA-N 0.000 description 1
- VGYBYGQXZJDZJU-XQXXSGGOSA-N Thr-Glu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VGYBYGQXZJDZJU-XQXXSGGOSA-N 0.000 description 1
- HJOSVGCWOTYJFG-WDCWCFNPSA-N Thr-Glu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O HJOSVGCWOTYJFG-WDCWCFNPSA-N 0.000 description 1
- KBLYJPQSNGTDIU-LOKLDPHHSA-N Thr-Glu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O KBLYJPQSNGTDIU-LOKLDPHHSA-N 0.000 description 1
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 1
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 1
- BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 description 1
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 1
- XEVHXNLPUBVQEX-DVJZZOLTSA-N Thr-Trp-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)O)N)O XEVHXNLPUBVQEX-DVJZZOLTSA-N 0.000 description 1
- PELIQFPESHBTMA-WLTAIBSBSA-N Thr-Tyr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 PELIQFPESHBTMA-WLTAIBSBSA-N 0.000 description 1
- DNUJCLUFRGGSDJ-YLVFBTJISA-N Trp-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CNC2=CC=CC=C21)N DNUJCLUFRGGSDJ-YLVFBTJISA-N 0.000 description 1
- AYHSJESDFKREAR-KKUMJFAQSA-N Tyr-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AYHSJESDFKREAR-KKUMJFAQSA-N 0.000 description 1
- IYHNBRUWVBIVJR-IHRRRGAJSA-N Tyr-Gln-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 IYHNBRUWVBIVJR-IHRRRGAJSA-N 0.000 description 1
- QHLIUFUEUDFAOT-MGHWNKPDSA-N Tyr-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QHLIUFUEUDFAOT-MGHWNKPDSA-N 0.000 description 1
- BYAKMYBZADCNMN-JYJNAYRXSA-N Tyr-Lys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O BYAKMYBZADCNMN-JYJNAYRXSA-N 0.000 description 1
- BIVIUZRBCAUNPW-JRQIVUDYSA-N Tyr-Thr-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O BIVIUZRBCAUNPW-JRQIVUDYSA-N 0.000 description 1
- XWYUBUYQMOUFRQ-IFFSRLJSSA-N Val-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N)O XWYUBUYQMOUFRQ-IFFSRLJSSA-N 0.000 description 1
- OACSGBOREVRSME-NHCYSSNCSA-N Val-His-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(O)=O OACSGBOREVRSME-NHCYSSNCSA-N 0.000 description 1
- WJVLTYSHNXRCLT-NHCYSSNCSA-N Val-His-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WJVLTYSHNXRCLT-NHCYSSNCSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- QIVPZSWBBHRNBA-JYJNAYRXSA-N Val-Pro-Phe Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O QIVPZSWBBHRNBA-JYJNAYRXSA-N 0.000 description 1
- DOFAQXCYFQKSHT-SRVKXCTJSA-N Val-Pro-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DOFAQXCYFQKSHT-SRVKXCTJSA-N 0.000 description 1
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 1
- QSPOLEBZTMESFY-SRVKXCTJSA-N Val-Pro-Val Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O QSPOLEBZTMESFY-SRVKXCTJSA-N 0.000 description 1
- LTTQCQRTSHJPPL-ZKWXMUAHSA-N Val-Ser-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N LTTQCQRTSHJPPL-ZKWXMUAHSA-N 0.000 description 1
- QZKVWWIUSQGWMY-IHRRRGAJSA-N Val-Ser-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QZKVWWIUSQGWMY-IHRRRGAJSA-N 0.000 description 1
- VVIZITNVZUAEMI-DLOVCJGASA-N Val-Val-Gln Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(N)=O VVIZITNVZUAEMI-DLOVCJGASA-N 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010020688 glycylhistidine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 108010060857 isoleucyl-valyl-tyrosine Proteins 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108010085203 methionylmethionine Proteins 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/46447—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本發明提供一種胜肽，含有序列編號1~12中之任一者所示之胺基酸序列中的連續8個以上之胺基酸殘基且由11個以下之胺基酸殘基構成。
Description
本發明係關於來自MUC1之胜肽，更具體而言，係關於藉由和人類白血球抗原的結合而將抗原呈現給T細胞之免疫原性胜肽、使用此胜肽之用於治療或預防癌之醫藥組成物、免疫誘導劑及抗原呈現細胞之製造方法等。
活體內據認為會隨時偶發地產生癌細胞，但預期通常會引發自然免疫所為之來自癌細胞之專一性癌抗原的排除反應，然後，誘導專一性免疫反應，並引發淋巴細胞等所為之癌細胞的排除反應。
為了辨認來自癌細胞的抗原，存在細胞表面上的人類白血球抗原(HLA)與淋巴細胞必須形成複合體。主要組織相容性抗原即HLA分子大致分為第一型分子(HLA-A型、B型、C型)與第二型分子(HLA-DP型、DQ型、DR型)。細胞傷害性T細胞(CTL)所為之癌細胞的排除反應係藉由癌細胞表面的HLA第一型分子所呈現之由8~11個胺基酸構成的癌抗原(CTL抗原決定位)受到CTL上的T細胞抗原受體(TCR)專一性地辨認而誘導。
目前，期待朝向各種免疫相關疾病的治療或預防之應用，而正在實施免疫原性胜肽的探尋，例如，日本特開平8-151396號公報記載有由特定的胺基酸序列構成之寡胜肽具有HLA結合性之要旨。 [先前技術文獻] [專利文獻]
[專利文獻1]日本特開平8-151396號公報
[發明所欲解決之課題] 已知有許多具有HLA結合性之胜肽，但進一步尋求可使用於各種癌的治療或預防之胜肽。又由於HLA係多型性豐富的基因，故亦要求有關對應於多種HLA型之多型免疫原性胜肽。 [解決課題之手段]
本發明係鑑於上述情事，其目的在於提供：結合於HLA第一型分子的免疫原性胜肽，尤其是能誘導CTL之胜肽、使用此胜肽之用於治療或預防癌之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法等。
亦即，本發明包含以下之發明： (1) 一種胜肽，含有序列編號1~12中之任一者所示之胺基酸序列中的連續8個以上之胺基酸殘基，且由11個以下之胺基酸殘基構成。 (2) 如(1)所記載之胜肽，其中，該胺基酸序列中有1個或數個胺基酸取代、***、缺失或附加，且具有免疫原性。 (3) 如(2)所記載之胜肽，其中，該胺基酸序列中，第2位之胺基酸以酪胺酸、***酸、甲硫胺酸、色胺酸、纈胺酸、白胺酸或麩醯胺酸取代，及/或C端之胺基酸以***酸、白胺酸、異白胺酸、色胺酸、甲硫胺酸或纈胺酸取代。 (4) 一種用於治療或預防癌之醫藥組成物，含有如(1)~(3)中任一項所記載之胜肽。 (5) 如(4)所記載之用於治療或預防癌之醫藥組成物，為疫苗之形態。 (6) 如(4)或(5)所記載之用於治療或預防癌之醫藥組成物，其中，該胜肽可與1種或多種類型之HLA分子結合。 (7) 一種免疫誘導劑，包含如(1)~(3)中任一項所記載之胜肽。 (8) 如(7)所記載之免疫誘導劑，用於誘導細胞傷害性T細胞。 (9) 如(7)或(8)所記載之免疫誘導劑，其中，該胜肽可與1種或多種類型之HLA分子結合。 (10) 一種具有CTL誘導活性之抗原呈現細胞之製造方法，包含以下步驟：如(1)~(3)中任一項所記載之胜肽與抗原呈現細胞在試管內(in vitro)接觸。 [發明之效果]
近年，免疫療法作為癌的治療方法而受到關注。由於本發明之胜肽與HLA結合性高，且CTL誘導能力亦高，故作為癌疫苗之有效性受到強烈的期待。又朝各種免疫療法，尤其朝樹狀細胞療法之應用亦受到預期。
黏蛋白(Mucin)係於正常及惡性之各種上皮細胞會表現之巨大的醣蛋白(Devine PL and McKenzie IF: Mucins: structure, function, and associations with malignancy. Bioessays14
: 619-625, 1992.) 為黏蛋白多肽之一的MUC1係貫穿細胞表面之細胞膜而表現之獨特的醣蛋白(Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN and Wilson D: Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem265
: 15286-15293, 1990.) 癌細胞具有的MUC1之醣化修飾不完全(Hanisch FG, Stadie TR, Deutzmann F and Peter-Katalinic J: MUC1 glycoforms in breast cancer – cell line T47D as a model for carcinoma-associated alterations of O-glycosylation. Eur J Biochem236
: 318-327, 1996.)，已有人報告在胰臟癌、乳癌、卵巢癌等有誘導針對MUC1之殺手T細胞的情況(20 Barnd DL, Lan MS, Metzgar RS and Finn OJ: Specific, major histocompatibility complex-unrestricted recognition of tumorassociated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA86
: 7159-7163, 1989. 21 Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, Bast RC Jr and Finn OJ: Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res51
: 2908-2916, 1991. 22 Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT and O'Brian CA: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu protooncogene. Cell Immunol151
: 225-234, 1993.)。 又，關於本發明之胜肽中之特定者可與多種HLA型結合。因此，根據本發明之胜肽，能提供涵蓋極廣範圍的癌患者群之癌疫苗、樹狀細胞療法等。
1.免疫原性胜肽 本發明相關之胜肽係含有序列編號1~12中之任一者所示之胺基酸序列中的連續8個以上之胺基酸殘基，且由合計11個以下，宜為10個以下，為9個以下更佳之胺基酸殘基構成之胜肽。本發明之胜肽亦可為由序列編號1~12之中任一者所示之胺基酸序列構成。本發明之胜肽來自腫瘤相關抗原中之一的黏蛋白1(MUC1)。 選擇基於構成MUC1之胺基酸序列，利用使用主動學習(active learning)實驗法(日本特開平11-316754號公報)而獲得之假說所預測之和HLA分子的結合性換算成-logKd值為3以上之胺基酸序列。
構成本發明之胜肽的胺基酸序列與其和HLA結合之預測分數係如下表1所示：。 [表1]
本發明之胜肽有HLA結合性，且具有免疫原性(以下亦有簡單稱為「HLA胜肽」或「免疫原性胜肽」之情況)。在本說明書使用時，「免疫原性」係意指可誘導免疫反應，例如意指具有CTL誘導活性，進而具有對癌細胞之細胞傷害活性之情事。
理想的態樣中，本發明之胜肽係可與多種HLA-A之基因A之等位基因(allele)型結合之多型HLA胜肽。例如序列編號10之胜肽與HLA-A*24：02基因的產物(HLA-A*24：02分子)、HLA-A*02：01基因的產物(HLA-A*02：01分子)及HLA-A*02：06基因的產物(HLA-A*02：06分子)強結合，同時具有高免疫原性。
能與本發明之胜肽結合的HLA亞型並不限於HLA-A*24：02、HLA-A*02：01及HLA-A*02：06。但是由於該等HLA亞型涵括約85%之包含日本人之東方人且涵括約55%之西方人，故據認為本發明之多型HLA胜肽在免疫療法等中具有廣泛的患者涵蓋率。
本發明之胜肽只要能保持免疫原性，亦可將構成序列編號1~12之胺基酸序列之胺基酸殘基或其中一部分進行修飾。雖然希望序列編號1~12所示之胺基酸序列呈現於抗原呈現細胞上之狀態，但將本發明之胜肽直接投予於體內時，依投予途徑有時會因消化器官等而有其末端受到消化等變化。因此，本發明之胜肽在抗原呈現細胞攝入前也可以在N端及/或C端附加1個或多個胺基酸殘基等之前驅體狀態存在，使其在抗原呈現細胞上和預定的HLA第一型分子結合時會保持序列編號1~12所示之胺基酸殘基。
此外，本發明之胜肽只要能具有期望的免疫原性，構成本發明之胜肽的1個或數個胺基酸殘基可取代、***、缺失或附加、亦或及/或有糖鏈的附加、側鏈的氧化、及/或磷酸化等修飾。本說明書中「胺基酸」使用其最廣的意義，除了包含天然胺基酸之外，亦包含人工胺基酸變異體、衍生物。本說明書中胺基酸可列舉：天然蛋白性L-胺基酸；D-胺基酸；胺基酸變異體及衍生物等經化學修飾之胺基酸；正白胺酸、β-丙胺酸、鳥胺酸等天然非蛋白性胺基酸；及具有胺基酸的特徵之發明所屬技術領域中具有通常知識者所公知的特性之經化學合成而得之化合物等。作為非天然胺基酸的例子可列舉：α-甲基胺基酸(α-甲基丙胺酸等)、D-胺基酸、類組胺酸胺基酸(β-羥基-組胺酸、高組胺酸(homohistidine)、α-氟甲基-組胺酸及α-甲基-組胺酸等)、側鏈具有額外的亞甲基之胺基酸(「同源」胺基酸)及側鏈中具羧酸官能基之胺基酸被磺酸基取代之胺基酸(半胱胺酸等)。
關於胺基酸殘基的取代等，考量對HLA展現結合性之胜肽序列的規則性(J. Immunol., 152: p3913, 1994; Immunogenetics, 41: p178, 1995; J. Immunol., 155: p4307, 1994)，該技術領域中具有通常知識者可適當地取代構成本發明之胜肽的胺基酸殘基。
更具體而言，為與HLA-A*24：02分子結合之胜肽時，構成胜肽之第2位的胺基酸可用酪胺酸、***酸、甲硫胺酸或色胺酸取代，及/或C端之胺基酸亦可用***酸、白胺酸、異白胺酸、色胺酸或甲硫胺酸取代。又，為與HLA-A*02：01分子結合之胜肽時，第2位之胺基酸可用白胺酸或甲硫胺酸取代，及/或C端之胺基酸亦可用纈胺酸或白胺酸取代。此外，為與HLA-A*02：06分子結合之胜肽時，第2位之胺基酸可用纈胺酸或麩醯胺酸取代，及/或C端之胺基酸亦可用纈胺酸或白胺酸取代。
本發明之胜肽均能使用該技術領域中具有通常知識者所公知的方法製造。例如可利用Fmoc法、tBoc法等固相法或液相法進行人工合成。又，亦可藉由使編碼本發明之胜肽的聚核苷酸或含有該聚核苷酸之重組載體表現而製造期望之胜肽。又，如此而得到的胜肽均能使用該技術領域中具有通常知識者已知的方法鑑定。例如能使用艾德曼降解(Edman degradation)法、質量分析法等鑑定。
2.醫藥組成物 本發明相關之用於治療或預防癌之醫藥組成物含有胜肽作為有效成分，該胜肽例如含有選自於由序列編號1~12構成之群組中1種以上之胺基酸序列中的連續8個以上之胺基酸殘基，且由合計11個以下，宜為10個以下，為9個以下更佳之胺基酸殘基構成。醫藥組成物所含之胜肽亦可由序列編號1~12之中任一者所示之胺基酸序列構成。該胜肽係如上文所定義。
本發明之胜肽係藉由呈現於抗原呈現細胞上而誘導CTL，且該經誘導之CTL會傷害癌細胞。因此，本發明之醫藥組成物的有效成分並不限於本發明之胜肽，亦可為能直接或間接地誘導CTL之成分，例如：編碼該胜肽之聚核苷酸或含有該聚核苷酸之載體、或將該胜肽與HLA分子之複合體呈現在表面之抗原呈現細胞或由抗原呈現細胞所分泌的外泌體(exosomes)、或該等之組合。作為所使用的抗原呈現細胞可列舉巨噬細胞、樹狀細胞等，宜使用CTL誘導能力高的樹狀細胞。本發明之醫藥組成物亦可含有已知使用於癌治療之其他成分，例如：趨化激素(chemokine)、細胞激素(cytokine)、腫瘤壞死因子、化學療法藥劑等。胜肽的用量例如患者為成人時可為1天約1~10mg。但是由於用量因應患者的年齡、體重、投予方法等而變動，故由該技術領域中具有通常知識者做適當地決定。
據認為本發明之醫藥組成物係利用以下之作用機制而對癌細胞之殺傷等有效，但不限定。藉由將本發明之醫藥組成物投予於特定之癌患者，醫藥組成物中的胜肽會以和HLA分子結合的狀態呈現在抗原呈現細胞表面。CTL辨認如此之抗原呈現細胞上的胜肽的話，會活化並增殖而進入體循環。對胜肽有專一性的CTL侵入癌組織的話，會辨認和來自與癌細胞表面之HLA分子自然地結合之專一性癌抗原相同的胜肽而殺傷該癌細胞。利用該作用可對癌的治療有所貢獻。
本發明之醫藥組成物不僅可使用於癌的治療，亦可使用於癌的預防。例如，藉由將本發明之醫藥組成物投予於健康的人體而誘導CTL，且經誘導之細胞傷害性T細胞會在體內留存，故當特定的癌細胞發生時，即可傷害該癌細胞。同樣地，藉由投予於經癌治療後的人體，亦可預防癌的復發。
預期所有表現MUC1的癌皆可作為受治療或預防的癌。更具體而言可列舉胰臟癌、肝細胞癌、***癌、肺癌、乳癌、大腸癌、血液癌(hematologic cancer)、腦腫瘤、腎臟癌、皮膚癌等作為對象，但不限定。例如，本發明之胜肽的來源即MUC1在胰臟癌會過量表現，故據認為本發明之胜肽尤其在胰臟癌的治療或預防係為有效。存在多種應予以治療或預防之癌時，可使本發明之醫藥組成物含有多種免疫原性胜肽等有效成分。
本發明之醫藥組成物可溶於水溶性溶劑中，以製藥上允許之鹽的形態進行製劑而投予於患者。作為如此之製藥上允許之鹽的形態可列舉生理上可接受之水溶性的鹽，例如鈉、鉀、鎂、鈣、等鹽的形式且以生理性的pH使其緩衝之形態。又，除了使用水溶性溶劑之外，亦可使用非水溶性溶劑，作為如此之非水溶性溶劑可列舉例如乙醇、丙二醇等醇。
又，在含有本實施形態之醫藥組成物的製劑中，亦可含有針對各種目的之藥劑，作為如此的藥劑可列舉例如保存劑、緩衝劑等。作為保存劑可列舉：亞硫酸氫鈉、硫酸氫鈉、硫代硫酸鈉、氯化苯二甲烴銨(benzalkonium chloride)、氯丁醇、硫柳汞(thimerosal)、乙酸苯汞、硝酸苯汞、對羥基苯甲酸甲酯、聚乙烯醇、苯乙醇、氨、二硫蘇糖醇、2-巰基乙醇等。又作為緩衝劑可列舉：碳酸鈉、硼酸鈉、磷酸鈉、乙酸鈉、碳酸氫鈉等。該等藥劑能以可將反應系的pH維持在2~9，宜為4~8之間的量而存在。
本發明之醫藥組成物的劑型亦無特別限制，作為疫苗之形態而使用時，其劑型可例示：注射劑(肌肉、皮下、皮內)、經口製劑、點鼻製劑等。本發明之醫藥組成物為疫苗之形態時，亦可為含有多種有效成分之混合雞尾酒疫苗。例如，如此的疫苗係序列編號1~12所示胜肽之中任2個以上，或和其他有效成分的組合，能含有多種有效成分。
又，本發明之疫苗亦可為含有醫藥組成物以外的成分之含不活性成分之疫苗，該成分本身無活性而具有更進一步提高醫藥組成物作為疫苗之效果的功效。作為不活性成分可列舉佐劑(adjuvant)、類毒素(toxoid)等。作為佐劑之例子可列舉：氫氧化鋁、磷酸鋁、磷酸鈣等沉降性型佐劑；弗氏完全佐劑、弗氏不完全佐劑等油性型佐劑，但目的並非為限定之用。
本發明之醫藥組成物以疫苗的形態存在時，宜為利用皮內、皮下、靜脈內、肌肉內投予等所為之注射或輸液、或經皮、或由鼻、咽頭等黏膜吸入等而投予於體內。其一次投予量可設定在能顯著地誘導細胞傷害性T細胞的量至不使顯著數量的非癌細胞受到傷害的量之間。
本發明之醫藥組成物不僅用於對人體之投予，亦可用於體外使用之目的。更具體而言，本發明之醫藥組成物亦可使用於將抗原呈現細胞在試管內或離體(ex vivo)下刺激而增加CTL誘導活性之用。例如以使用於癌樹狀細胞療法時為例進行說明的話，將本發明之醫藥組成物事先與來自有必要進行癌的治療或預防之患者的樹狀細胞等之抗原呈現細胞接觸後，藉由將此抗原呈現細胞回輸至患者體內而能投予於患者。醫藥組成物所含之胜肽例如可利用脂質體轉染法(lipofection)、注射法等導入抗原呈現細胞內。在如此的用途中使用編碼本發明之胜肽的聚核苷酸時，聚核苷酸能利用發明所屬技術領域中具有通常知識者所公知的方法導入到抗原呈現細胞。例如亦可利用脂質體轉染法、電穿孔法、顯微注射法、細胞融合法、DEAE葡聚糖法、磷酸鈣法等，在試管內以對象之聚核苷酸或編碼聚核苷酸之載體將來自患者的抗原呈現細胞進行轉型等。
3.免疫誘導劑 本發明相關之免疫誘導劑例如含有選自於由序列編號1~12構成之群組中之1種以上之胺基酸序列中的連續8個以上之胺基酸殘基，且由合計11個以下，宜為10個以下，為9個以下更佳之胺基酸殘基構成的胜肽作為有效成分。免疫誘導劑所含之胜肽亦可由序列編號1~12中之任一者所示之胺基酸序列構成。該胜肽係如上文所定義。
據認為本發明之胜肽係藉由呈現於抗原呈現細胞上而誘導免疫。因此，本發明之免疫誘導劑的有效成分並不限於本發明之胜肽，亦可為能直接或間接地誘導免疫之成分，例如：編碼本發明之胜肽之聚核苷酸或含有該聚核苷酸之表現載體、或將該胜肽與HLA分子的複合體呈現於表面之抗原呈現細胞或由抗原呈現細胞所分泌之外泌體、或該等之組合。作為所使用的抗原呈現細胞可列舉巨噬細胞、樹狀細胞等，宜使用CTL誘導能力高的樹狀細胞。
本發明之免疫誘導劑不僅用於對人體之投予，亦可用於體外使用之目的。更具體而言，本發明之免疫誘導劑亦可使用於將抗原呈現細胞在試管內或離體下刺激而增加CTL誘導活性之用。例如以使用於樹狀細胞療法時為例進行說明的話，將本發明之免疫誘導劑事先與來自有必要進行免疫誘導之患者的樹狀細胞等之抗原呈現細胞接觸後，藉由將此抗原呈現細胞回輸至患者體內而能投予於患者。免疫誘導劑所含之胜肽例如可利用脂質體介導之轉染(脂質體轉染法)、注射法等導入到抗原呈現細胞內。在如此的用途中使用編碼本發明之胜肽的聚核苷酸時，聚核苷酸能利用發明所屬技術領域中具有通常知識者所公知的方法導入到抗原呈現細胞。例如亦可利用脂質體轉染法、電穿孔法、顯微注射法、細胞融合法、DEAE葡聚糖法、磷酸鈣法等，在試管內以對象之聚核苷酸或表現聚核苷酸之載體將來自患者的抗原呈現細胞進行轉型等。
在本說明書使用時，「免疫誘導」係指誘導免疫反應，例如：使抗原呈現細胞之CTL誘導活性增加，並進一步使CTL之對於癌細胞的細胞傷害活性增加之情事。又，在本說明書使用時，「CTL誘導」係指在試管內或在體內(in vivo)，本發明之胜肽藉由呈現於抗原呈現細胞表面上而誘導或增殖專一性地辨認某抗原之CTL、或使初始T細胞(naive T cell)朝向具有殺傷癌細胞等標的細胞的能力(細胞傷害活性)之作用細胞(effector cell)分化、及/或使CTL之細胞傷害活性增加之情事。CTL誘導活性可藉由評估源於CTL之細胞激素(例如干擾素(IFN)-γ)的產生而進行測量。例如亦可藉由使用ELISPOT(酵素連結免疫斑點法，Enzyme-Linked ImmunoSpot)法或ELISA(酵素連結免疫吸附法，Enzyme-Linked ImmunoSorbent Assay)法等公知之高感度免疫分析評估經本發明之胜肽刺激之週邊血液單核細胞(peripheral blood mononuclear cells)等之抗原呈現細胞所致由前驅細胞誘導而成之產生細胞激素的細胞之增加，而測量CTL誘導活性。細胞傷害活性亦可利用51
Cr游離法等公知的方法測量。上述活性與對照組比較有顯著地增加時，例如增加5%以上、10%以上、20%以上、宜為50%以上時，可評價為免疫或CTL受到誘導。
4.抗原呈現細胞之製造方法 本發明相關之抗原呈現細胞之製造方法包含下述步驟：例如使含有選自於由序列編號1~12構成之群組中之1種以上之胺基酸序列中的連續8個以上之胺基酸殘基，且由合計11個以下，宜為10個以下，為9個以下更佳之胺基酸殘基構成的胜肽與抗原呈現細胞在試管內接觸。本發明之製造方法所使用的胜肽亦可由序列編號1~12中之任一者所示之胺基酸序列構成。該胜肽係如上文所定義。
本發明之製造方法所使用的胜肽據認為會與抗原呈現細胞表面的HLA第一型分子結合，並作為抗原胜肽而呈現給CTL，藉此誘導抗原呈現細胞之CTL活性。因此，和抗原呈現細胞接觸的並不限於本發明之胜肽，亦可為能直接或間接地誘導CTL之成分，例如編碼該胜肽之聚核苷酸或含有該聚核苷酸之載體，或將該胜肽與HLA分子的複合體呈現於表面之抗原呈現細胞或由抗原呈現細胞所分泌之外泌體，或該等之組合。作為所使用的抗原呈現細胞可列舉巨噬細胞、樹狀細胞等，宜使用CTL誘導能力高的樹狀細胞。
利用本發明之製造方法製造的抗原呈現細胞不僅使用作為上述醫藥組成物或免疫誘導劑之有效成分，亦可使用於免疫療法等之用的目的。例如以使用於癌樹狀細胞療法時為例進行說明的話，將製得的抗原呈現細胞事先與來自有必要進行免疫誘導之患者之CTL誘導能力低的樹狀細胞等之抗原呈現細胞接觸後，藉由將此抗原呈現細胞回輸至患者體內而能投予於患者。本發明之胜肽例如可利用脂質體介導之轉染(脂質體轉染法)、注射法等導入抗原呈現細胞內。在如此的用途中使用編碼本發明之胜肽之聚核苷酸時，聚核苷酸能利用發明所屬技術領域中具有通常知識者所公知的方法導入抗原呈現細胞。例如亦可利用脂質體轉染法、電穿孔法、顯微注射法、細胞融合法、DEAE葡聚糖法、磷酸鈣法等，在試管內以對象之聚核苷酸或編碼聚核苷酸之載體將來自患者的抗原呈現細胞進行轉型等。 [實施例1]
以下舉實施例更具體地說明本發明，但本發明並不受限於該等實施例。
具體而言，本實施例中的預測･實驗･評估之程序係基於國際公開2006/004182號小冊所記載之主動學習實驗設計(active learning experiment design)而實施，整體而言重複以下步驟而建構規則。
(1) 實施一次後述之下位學習演算法之試驗。亦即，由累計資料之隨機採樣顯現出多種假設，並選出相對於隨機顯現之問題候選點(胜肽)之預測值的變量最大的點作為應予以實驗之問題點。
(2) 將選出問題點之胜肽利用後述之合成･純化法製造，並利用後述之實驗測量實際的結合能力而加入累計資料中。
藉由實施如此的主動學習法，可減少本來針對由9個胺基酸殘基構成的胜肽有必要實施關於HLA結合性胜肽之所有候選物質5000億(=209
)次以上之結合實驗的數量。
根據如上說明之規則，選出序列編號1~12所示之胺基酸序列。
＜胜肽合成與純化＞ 具有序列編號1~12之胺基酸序列的胜肽係使用Fmoc胺基酸，並以梅里菲爾德(Merrifield)固相法進行人工合成。脱保護之後，使用C18管柱進行逆相HPLC純化並達到95%以上之純度。胜肽之鑑定與純度之確認係利用MALDI-TOF質量分析實施(AB SCIEX MALDI-TOF/TOF5800)。胜肽之定量係以BSA作為標準蛋白質利用Micro BCA Assay(Thermo Scientific公司)實施。
＜胜肽結合至HLA-A*24：02分子的實驗＞ 胜肽結合至HLA-A*24：02基因之產物即HLA-A*24：02分子的能力之測量係使用表現HLA-A*24：02分子之C1R-A24細胞(熊本大學，瀧口雅文教授所製得之細胞，經取得許可而由愛媛大學，安川正貴助教授提供)實施。
首先，將C1R-A24細胞於pH3.3之酸性條件下暴露30秒，將原本結合於HLA-A*24：02分子的內生性胜肽與HLA第一型分子所共通而締合之輕鏈β2m解離並去除。中和後，將純化之β2m加入到C1R-A24細胞，並添加至系列稀釋之胜肽中，冰上培養4小時。在此期間使用可辨認再締合而成之HLA-A*24：02分子、胜肽、β2m之3者的締合體(MHC-pep)之螢光標識單株抗體17A12進行染色。
其後，使用螢光細胞分析裝置FACScan(Becton-Dickinson公司)定量測量各個C1R-A24細胞所相當之MHC-pep數(和上述螢光抗體之螢光強度成比例)。利用本案發明人於論文(Udaka et al., Immunogenetics, 51, 816-828, 2000)所發表的方法，由每1個細胞之平均螢光強度計算HLA-A*24：02分子與胜肽間的結合解離常數Kd值。
＜胜肽結合至HLA-A*02：01分子的實驗＞ 胜肽結合至HLA-A*02：01基因之產物即HLA-A*02：01分子的能力之測量係使用表現HLA-A*02：01分子之細胞株T2(購自ATCC)實施。
在欲測量結合能力之階段系列稀釋之胜肽中加入T2細胞與純化之β2m後，於37℃培養4小時。達此時間點時使用締合型專一性螢光標識單株抗體BB7.2，將因胜肽之濃度依存性而表現量增加的HLA-A*02：01分子染色。
其後，利用流式細胞儀(flow cytometer)測量每1個細胞之螢光量，並以本案發明人於論文(Udaka et al.,Immunogenetics, 51, 816-828, 2000)所發表的方法計算解離常數Kd值。
＜胜肽結合至HLA-A*02：06分子的實驗＞ 胜肽結合至HLA-A*02：06基因之產物即HLA-A*02：06分子的能力之測量係使用於老鼠之TAP(transporter associated with antigen processing)缺損細胞株即RMAS中導入HLA-A*02：06基因之cDNA的RA2.6細胞(於高知大學新製得之細胞株)實施。
首先將RA2.6細胞於26℃培養隔夜，當細胞表面聚積了未與胜肽結合之HLA-A*02：06分子後加入系列稀釋之胜肽，並於26℃使其結合60分鐘。
其後藉由於35℃培養4小時，未結合胜肽之空的HLA-A*02：06分子會變性並失去立體結構。於此加入專一性地辨認胜肽結合型HLA-A*02：06分子之螢光標識單株抗體BB7.2，並於冰上培養20分鐘，將細胞染色。
其後，利用流式細胞儀測量每1個細胞之螢光量，並以本案發明人於論文(Udaka et al.,Immunogenetics, 51, 816-828, 2000)所發表的方法計算解離常數Kd值。
＜結合實驗的評估結果＞ 其結果得到如下表所示之對於各HLA分子之本發明之胜肽的結合實驗資料。 [表2]
另外，序列編號1~12之胺基酸序列係來自登錄於GENBANK之MUC1既定的基因體蛋白質之全長序列(序列編號13)(＞sp|P15941|MUC1_HUMAN Mucin-1 OS=Homo sapiens GN=MUC1 PE=1 SV=3)。
＜胜肽之免疫誘導試驗＞ (1) 胜肽刺激樹狀細胞的製備 ･Day0~9(樹狀細胞的誘導) 將利用分離法(pheresis)從已接受針對MUC1之樹狀細胞/CTL療法之患者得到的週邊血液單球之中，黏著於培養角瓶之細胞分部(fraction)，在AIM-CM培養基(Gibco公司製)中，於37℃培養10天。在培養期間之第0天及第3天各別對培養基添加15μl之IL-4、30μL之顆粒球單核球群落刺激因子(GM-CSF)，並於第5天添加15μl之IL-4、30μl之GM-CSF、75μl之腫瘤壞死因子(TNF)-α。
･Day10(胜肽刺激及樹狀細胞的回收) 將誘導後之樹狀細胞回收至新的AIM-CM培養基中，並添加本發明之胜肽(序列編號1~12)使其濃度成為20μg/ml。其後，將含有樹狀細胞之培養基於37℃培養2小時。使用以下的胜肽作為正對照組及負對照組。 HLA-A*24：02用正對照組(EBV LMP2, 419-427:TYGPVFMCL(序列編號14)) HLA-A*24：02用負對照組(HIV env gp160, 584-592:RYLRDQQLL(序列編號15)) HLA-A*02：01用正對照組(Flu A MP, 58-66:GILGFVFTL(序列編號16)) HLA-A*02：01用負對照組(HIV gap p17, 77-85:SLYNTVATL(序列編號17)) HLA-A*02：06用正對照組(EBV LMP2 453-461:LTAGFLIFL(序列編號18)) HLA-A*02：06用負對照組(HIV gap p24 341-349:ATLEEMMTA(序列編號19))
回收樹狀細胞並以充分的量之AIM-CM培養基洗淨3次以上之後進行細胞計數。
(2) CD8T細胞的製備 ･Day0~9 將利用分離法從已用上述疫苗進行2次以上治療後之患者得到的週邊血液單球之中，未黏著於培養角瓶之浮游細胞分部(包含淋巴細胞)在AIM-CM培養基(Gibco公司製)中，於37℃培養10天。在培養期間之第4天及第6天各別對培養基添加40μl之IL-2。
･Day10 使用CD8負向選擇套組(Miltenyi公司製)從培養基分離CD8 T細胞並進行細胞計數。
(3) 共培養 將上述(1)及(2)所得到的樹狀細胞與CD8T細胞在以下的條件於AIM-CM培養基中以37℃共培養。 ･CD8T細胞：5×105
個細胞/孔 ･樹狀細胞：2×105
個細胞/孔
･Day12或13 於上述培養基中以0.4ml/孔的方式添加含有20U/ml之IL-2的AIM-CM培養基。
(5) ELISA分析法 ･Day17 將T細胞與上述利用胜肽進行脈衝之樹狀細胞共培養第7天之培養上清液進行1倍、5倍、25倍、125倍之4階段稀釋，並使用Human IFN-γ ELISA MAX Deluxe Set(BioLegend公司製)鑑定落入測量限度內之稀釋階段。其後，以鑑定得到的稀釋階段針對每個樣本實施3次的測量。就典型的ELISA分析的結果而言，針對HLA型為24：02/33：03之患者、24：02/33：03之患者、02：06/24：02之患者、02：01/02：06之患者的結果按順序如圖1~4所示。
以上根據實施例說明本發明。該實施例僅為例示，該技術領域中具有通常知識者應理解各種變形例皆為可能，且如此之變形例亦包含在本發明之範圍內。
無
[圖1] 圖1係表示以序列編號1、3、5或10之胜肽刺激來自已接受針對MUC1之樹狀細胞/CTL療法之患者(HLA型：24：02/33：03)的樣本時之ELISA分析的結果(產生IFN-γ的細胞數)。 [圖2] 圖2係表示以序列編號1、3、5或10之胜肽刺激來自已接受針對MUC1之樹狀細胞/CTL療法之患者(HLA型：24：02/33：03)的樣本時之ELISA分析的結果(產生IFN-γ的細胞數)。 [圖3] 圖3係表示以序列編號1、3、5或10之胜肽刺激來自已接受針對MUC1之樹狀細胞/CTL療法之患者(HLA型：02：06/24：02)的樣本時之ELISA分析的結果(產生IFN-γ的細胞數)。 [圖4] 圖4係表示以序列編號1、2、3、5、10或11之胜肽刺激來自已接受針對MUC1之樹狀細胞/CTL療法之患者(HLA型：02：01/02：06)的樣本時之ELISA分析的結果(產生IFN-γ的細胞數)。
無
＜110＞ 日本電氣股份有限公司 ＜120＞ 來自MUC1之胜肽、使用此胜肽之用於治療或預防癌之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法 ＜130＞ 6470098013 ＜150＞ JP2015-46462 ＜151＞ 2015-03-09 ＜160＞ 19 ＜170＞ PatentIn version 3.5 ＜210＞ 1 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人(Homo sapiens) ＜400＞ 1 Phe Leu Gly Leu Ser Asn Ile Lys Phe 1 5 ＜210＞ 2 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 2 Ser Val Pro Val Thr Arg Pro Ala Leu 1 5 ＜210＞ 3 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 3 Gly Val Pro Gly Trp Gly Ile Ala Leu 1 5 ＜210＞ 4 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 4 Ala Phe Arg Glu Gly Thr Ile Asn Val 1 5 ＜210＞ 5 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 5 Ala Ala Ser Arg Tyr Asn Leu Thr Ile 1 5 ＜210＞ 6 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 6 Leu Gln Arg Asp Ile Ser Glu Met Phe 1 5 ＜210＞ 7 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 7 His His Ser Asp Thr Pro Thr Thr Leu 1 5 ＜210＞ 8 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 8 Ser Phe Phe Phe Leu Ser Phe His Ile 1 5 ＜210＞ 9 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 9 Thr Leu Ala Phe Arg Glu Gly Thr Ile 1 5 ＜210＞ 10 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 10 Ser Thr Gly Val Ser Phe Phe Phe Leu 1 5 ＜210＞ 11 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 11 Gly Gln Asp Val Thr Ser Val Pro Val 1 5 ＜210＞ 12 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 12 Phe Ser Ala Gln Ser Gly Ala Gly Val 1 5 ＜210＞ 13 ＜211＞ 1255 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 13 Met Thr Pro Gly Thr Gln Ser Pro Phe Phe Leu Leu Leu Leu Leu Thr 1 5 10 15 Val Leu Thr Val Val Thr Gly Ser Gly His Ala Ser Ser Thr Pro Gly 20 25 30 Gly Glu Lys Glu Thr Ser Ala Thr Gln Arg Ser Ser Val Pro Ser Ser 35 40 45 Thr Glu Lys Asn Ala Val Ser Met Thr Ser Ser Val Leu Ser Ser His 50 55 60 Ser Pro Gly Ser Gly Ser Ser Thr Thr Gln Gly Gln Asp Val Thr Leu 65 70 75 80 Ala Pro Ala Thr Glu Pro Ala Ser Gly Ser Ala Ala Thr Trp Gly Gln 85 90 95 Asp Val Thr Ser Val Pro Val Thr Arg Pro Ala Leu Gly Ser Thr Thr 100 105 110 Pro Pro Ala His Asp Val Thr Ser Ala Pro Asp Asn Lys Pro Ala Pro 115 120 125 Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 130 135 140 Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 145 150 155 160 Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 165 170 175 Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 180 185 190 Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 195 200 205 Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 210 215 220 Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 225 230 235 240 Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 245 250 255 Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 260 265 270 Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 275 280 285 Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 290 295 300 Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 305 310 315 320 Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 325 330 335 Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 340 345 350 Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 355 360 365 Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 370 375 380 Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 385 390 395 400 Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 405 410 415 Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 420 425 430 Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 435 440 445 Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 450 455 460 Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 465 470 475 480 Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 485 490 495 Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 500 505 510 Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 515 520 525 Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 530 535 540 Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 545 550 555 560 Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 565 570 575 Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 580 585 590 Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 595 600 605 Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 610 615 620 Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 625 630 635 640 Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 645 650 655 Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 660 665 670 Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 675 680 685 Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 690 695 700 Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 705 710 715 720 Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 725 730 735 Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 740 745 750 Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 755 760 765 Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 770 775 780 Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 785 790 795 800 Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 805 810 815 Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 820 825 830 Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 835 840 845 Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr 850 855 860 Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser 865 870 875 880 Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His 885 890 895 Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala 900 905 910 Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro 915 920 925 Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Asn 930 935 940 Arg Pro Ala Leu Gly Ser Thr Ala Pro Pro Val His Asn Val Thr Ser 945 950 955 960 Ala Ser Gly Ser Ala Ser Gly Ser Ala Ser Thr Leu Val His Asn Gly 965 970 975 Thr Ser Ala Arg Ala Thr Thr Thr Pro Ala Ser Lys Ser Thr Pro Phe 980 985 990 Ser Ile Pro Ser His His Ser Asp Thr Pro Thr Thr Leu Ala Ser His 995 1000 1005 Ser Thr Lys Thr Asp Ala Ser Ser Thr His His Ser Ser Val Pro 1010 1015 1020 Pro Leu Thr Ser Ser Asn His Ser Thr Ser Pro Gln Leu Ser Thr 1025 1030 1035 Gly Val Ser Phe Phe Phe Leu Ser Phe His Ile Ser Asn Leu Gln 1040 1045 1050 Phe Asn Ser Ser Leu Glu Asp Pro Ser Thr Asp Tyr Tyr Gln Glu 1055 1060 1065 Leu Gln Arg Asp Ile Ser Glu Met Phe Leu Gln Ile Tyr Lys Gln 1070 1075 1080 Gly Gly Phe Leu Gly Leu Ser Asn Ile Lys Phe Arg Pro Gly Ser 1085 1090 1095 Val Val Val Gln Leu Thr Leu Ala Phe Arg Glu Gly Thr Ile Asn 1100 1105 1110 Val His Asp Val Glu Thr Gln Phe Asn Gln Tyr Lys Thr Glu Ala 1115 1120 1125 Ala Ser Arg Tyr Asn Leu Thr Ile Ser Asp Val Ser Val Ser Asp 1130 1135 1140 Val Pro Phe Pro Phe Ser Ala Gln Ser Gly Ala Gly Val Pro Gly 1145 1150 1155 Trp Gly Ile Ala Leu Leu Val Leu Val Cys Val Leu Val Ala Leu 1160 1165 1170 Ala Ile Val Tyr Leu Ile Ala Leu Ala Val Cys Gln Cys Arg Arg 1175 1180 1185 Lys Asn Tyr Gly Gln Leu Asp Ile Phe Pro Ala Arg Asp Thr Tyr 1190 1195 1200 His Pro Met Ser Glu Tyr Pro Thr Tyr His Thr His Gly Arg Tyr 1205 1210 1215 Val Pro Pro Ser Ser Thr Asp Arg Ser Pro Tyr Glu Lys Val Ser 1220 1225 1230 Ala Gly Asn Gly Gly Ser Ser Leu Ser Tyr Thr Asn Pro Ala Val 1235 1240 1245 Ala Ala Thr Ser Ala Asn Leu 1250 1255 ＜210＞ 14 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 14 Thr Tyr Gly Pro Val Phe Met Cys Leu 1 5 ＜210＞ 15 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 15 Arg Tyr Leu Arg Asp Gln Gln Leu Leu 1 5 ＜210＞ 16 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 16 Gly Ile Leu Gly Phe Val Phe Thr Leu 1 5 ＜210＞ 17 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 17 Ser Leu Tyr Asn Thr Val Ala Thr Leu 1 5 ＜210＞ 18 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 18 Leu Thr Ala Gly Phe Leu Ile Phe Leu 1 5 ＜210＞ 19 ＜211＞ 9 ＜212＞ PRT ＜213＞ 智人 ＜400＞ 19 Ala Thr Leu Glu Glu Met Met Thr Ala 1 5
無
Claims (10)
- 一種胜肽，含有序列編號1~12中之任一者所示之胺基酸序列中的連續8個以上之胺基酸殘基，且由11個以下之胺基酸殘基構成。
- 如申請專利範圍第1項之胜肽，其中，該胺基酸序列中有1個或數個胺基酸取代、***、缺失或附加，且具有免疫原性。
- 如申請專利範圍第2項之胜肽，其中，該胺基酸序列中，第2位之胺基酸以酪胺酸、***酸、甲硫胺酸、色胺酸、纈胺酸、白胺酸或麩醯胺酸取代，及/或C端之胺基酸以***酸、白胺酸、異白胺酸、色胺酸、甲硫胺酸或纈胺酸取代。
- 一種用於治療或預防癌之醫藥組成物，含有如申請專利範圍第1至3項中任一項之胜肽。
- 如申請專利範圍第4項之用於治療或預防癌之醫藥組成物，為疫苗之形態。
- 如申請專利範圍第4或5項之用於治療或預防癌之醫藥組成物，其中，該胜肽可與1種或多種類型之HLA分子結合。
- 一種免疫誘導劑，包含如申請專利範圍第1至3項中任一項之胜肽。
- 如申請專利範圍第7項之免疫誘導劑，用於誘導細胞傷害性T細胞。
- 如申請專利範圍第7或8項之免疫誘導劑，其中，該胜肽可與1種或多種類型之HLA分子結合。
- 一種具有CTL誘導活性之抗原呈現細胞之製造方法，包含以下步驟：將如申請專利範圍第1至3項中任一項之胜肽與抗原呈現細胞在試管內(in vitro)接觸。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015046462 | 2015-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201639868A true TW201639868A (zh) | 2016-11-16 |
Family
ID=56880033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105107134A TW201639868A (zh) | 2015-03-09 | 2016-03-09 | 來自muc1之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20180057531A1 (zh) |
| EP (1) | EP3269726A4 (zh) |
| JP (1) | JP6481873B2 (zh) |
| TW (1) | TW201639868A (zh) |
| WO (1) | WO2016143814A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023163094A1 (ja) * | 2022-02-25 | 2023-08-31 | 日本電気株式会社 | 成人ｔ細胞白血病の治療又は予防のための医薬組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08151396A (ja) | 1994-11-28 | 1996-06-11 | Teijin Ltd | Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤 |
| JPH11316754A (ja) | 1998-05-06 | 1999-11-16 | Nec Corp | 実験計画法及び実験計画プログラムを記録した記録媒体 |
| DK1210430T3 (da) * | 1999-09-08 | 2006-11-20 | Transgene Sa | MUC-1-afledte peptider |
| US20090144209A1 (en) | 2004-07-07 | 2009-06-04 | Nec Corporation | Sequence prediction system |
| US20090023895A1 (en) | 2006-02-07 | 2009-01-22 | Nec Corporation | Hla-binding peptide, precursor thereof, and dna fragment and recombinant vector coding for said hla-binding peptide |
| EP2337795A2 (en) * | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| CA2892369A1 (en) * | 2012-12-04 | 2014-06-12 | Oncotherapy Science, Inc. | Sema5b peptides and vaccines containing the same |
| CN104211796A (zh) * | 2013-11-09 | 2014-12-17 | 深圳市康尔诺生物技术有限公司 | 胰腺癌相关肽和热休克蛋白形成的复合物及其应用 |
-
2016
- 2016-03-09 US US15/556,766 patent/US20180057531A1/en not_active Abandoned
- 2016-03-09 WO PCT/JP2016/057349 patent/WO2016143814A1/ja active Application Filing
- 2016-03-09 JP JP2017505372A patent/JP6481873B2/ja active Active
- 2016-03-09 TW TW105107134A patent/TW201639868A/zh unknown
- 2016-03-09 EP EP16761781.0A patent/EP3269726A4/en active Pending
-
2020
- 2020-02-19 US US16/795,391 patent/US11618770B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6481873B2 (ja) | 2019-03-13 |
| US11618770B2 (en) | 2023-04-04 |
| WO2016143814A1 (ja) | 2016-09-15 |
| US20180057531A1 (en) | 2018-03-01 |
| JPWO2016143814A1 (ja) | 2018-01-18 |
| US20200181195A1 (en) | 2020-06-11 |
| EP3269726A4 (en) | 2018-12-05 |
| EP3269726A1 (en) | 2018-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI714558B (zh) | 來自gpc3之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法 | |
| CA2659124A1 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
| AU2018274976B2 (en) | Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell | |
| IL295031A (en) | Innovative immunotherapy against several tumors, such as lung cancer, including nsclc | |
| DK2435567T3 (en) | CDC45L PEPTIDES AND VACCINES INCLUDING THESE | |
| US11618770B2 (en) | MUC1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using same | |
| KR20170040315A (ko) | Cdca1-유래 펩티드 및 이를 포함하는 백신 | |
| WO2023163094A1 (ja) | 成人ｔ細胞白血病の治療又は予防のための医薬組成物 | |
| KR20220165831A (ko) | Urlc10-유래 펩티드 및 이를 포함하는 백신 |